title: Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
abstract: OBJECTIVE
  The association of antipsychotics is a widespread therapeutic resource in clinical practice. The purpose of the present work was to evaluate the efficacy and safety of amisulpride augmentation in patients responding at least partially to olanzapine.
  
  
  METHODS
  In this observational 3-months open-label investigation, we evaluated the effectiveness of the addition of amisulpride to 49 subjects, after having scored at least 25 on the brief psychiatric rating scale (BPRS) following olanzapine monotherapy for 6 weeks. Patients were assessed at baseline, 1 and 3 months using the BPRS, the clinical global impression severity of illness (CGI-S) scale and the Udvalg for Kliniske Undersogelser side effect rating scale (UKU).
  
  
  RESULTS
  In subjects who were at least partially responsive to monotherapy with olanzapine, coadjuvant treatment with amisulpride achieved a statistically significant improvement in mental status over a 3 month period as measured by the BPRS, CGI and UKU scales. The response rate (>20% reduction in BPRS score) was 75.51%.
  
  
  CONCLUSIONS
  Amisulpride augmentation, in a group of patients partially or non-responsive to olanzapine, may lead to an improvement in schizophrenic symptoms. However, these results are subject to several limitations making it difficult to derive firm clinical recommendations, and underscoring the need for future research into the value of these therapeutic alternatives in poor responders.
authors.affiliation: Acute In-Patient Unit, Dr. R. Lafora Psychiatric Hospital, Madrid, Spain. candrader@medynet.com
authors.forename: J D
authors.initials: JD
authors.lastname: Molina
authors.forename: F
authors.initials: F
authors.lastname: Toledo-Romero
authors.forename: E
authors.initials: E
authors.lastname: López-Rodríguez
authors.forename: M
authors.initials: M
authors.lastname: Amorin-Díaz
authors.forename: I
authors.initials: I
authors.lastname: Lerma-Carrillo
authors.forename: F
authors.initials: F
authors.lastname: López-Muñoz
mesh_terms: D000293:Adolescent; D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000503:physiopathology; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000077582:Amisulpride; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018492:Dopamine Antagonists; D000077152:Olanzapine; D017367:Selective Serotonin Reuptake Inhibitors; D013469:Sulpiride